<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="240">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695119</url>
  </required_header>
  <id_info>
    <org_study_id>SICU-II</org_study_id>
    <nct_id>NCT04695119</nct_id>
  </id_info>
  <brief_title>Sepsis in the ICU-II</brief_title>
  <official_title>Sepsis in the Intensive Care Unit-II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitaux Universitaires Paris Sud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Dupuytren</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU Dijon Bourgogne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis-induced cardiac dysfunction (SIMD) is a well-known phenomenon yet its diagnosis&#xD;
      remains elusive with no accepted definition, or defining pathophysiological mechanism&#xD;
      associated with this disease. Systolic dysfunction occurs in 20-70% of patients, and may be&#xD;
      severe, yet does not appear to have any prognostic value for mortality. Diastolic function&#xD;
      has also been variably described and seems to be related to short-term mortality. However,&#xD;
      the contribution of left ventricular systolic and diastolic dysfunction to mortality in&#xD;
      sepsis are still far from clear, with uncertain contribution from previous cardiovascular&#xD;
      disease, vasopressor and inotropic drugs and mechanical ventilation. Another poorly&#xD;
      investigated area is right ventricular dysfunction. Cor pulmonale occurs in up to 25% of&#xD;
      patients with septic shock, and is invariably related to pulmonary haemodynamics and&#xD;
      mechanical ventilation, yet very little is known about how this affects prognosis. Finally,&#xD;
      although the outcome of disease is a function of multiple parameters, septic cardiomyopathy&#xD;
      is most frequently characterized based on individual echocardiographic parameters, without&#xD;
      considering their interactions or placing them in the context of biomarkers and clinically&#xD;
      available haemodynamic data. Available relevant studies are often monocentric, and many fail&#xD;
      to consider the various confounders that influence the clinical outcome in sepsis. Therefore,&#xD;
      the diagnostic and prognostic value of combinations of clinical, biochemical and haemodynamic&#xD;
      variables remains to be established.&#xD;
&#xD;
      Accordingly, the purpose of this study is to identify biomarkers and echocardiographic and&#xD;
      haemodynamic signatures characteristic of specific outcomes in SIMD to support the diagnosis&#xD;
      and prognosis in SIMD. Specific aims are:&#xD;
&#xD;
        1. To determine the association between left ventricular systolic and diastolic&#xD;
           dysfunction, and adverse outcome in SIMD;&#xD;
&#xD;
        2. To determine the association between right ventricular systolic and diastolic&#xD;
           dysfunction, and adverse outcome in SIMD;&#xD;
&#xD;
        3. To determine the association between novel biomarkers and adverse outcome in SIMD;&#xD;
&#xD;
        4. To determine the combined value of biomarker, echocardiographic, and haemodynamic&#xD;
           variables for predicting adverse outcomes in SIMD;&#xD;
&#xD;
        5. To explore if there are different phenotypes of SIMD using unsupervised machine learning&#xD;
           algorithms, and whether they are associated with adverse outcomes.&#xD;
&#xD;
      30 patients will be enrolled in a feasibility study to evaluate the logistical setup for&#xD;
      acute echocardiography and biobanking facilities. A further 300 patients will be enrolled&#xD;
      with inclusion from peripheral centers once feasibility is confirmed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial injury</measure>
    <time_frame>any time during ICU stay within the study period, up to 10 days</time_frame>
    <description>increased hsTnT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ failure free days</measure>
    <time_frame>30 days of study inclusion</time_frame>
    <description>Organ failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 day mortality</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Short term mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>365 day mortality</measure>
    <time_frame>365 days after study inclusion</time_frame>
    <description>Long term mortality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory outcomes</measure>
    <time_frame>during ICU stay, up to 10 days</time_frame>
    <description>Vasopressor inotropic score</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcomes</measure>
    <time_frame>30 days of study inclusion</time_frame>
    <description>Days free of mechanical ventilation</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Septic Shock</condition>
  <condition>Sepsis</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Organ Failure, Multiple</condition>
  <arm_group>
    <arm_group_label>Adult patients with septic shock</arm_group_label>
    <description>All adult (&gt;=18 yo) patients admitted to participating ICUs with septic shock defined according to the Sepsis III criteria.&#xD;
Purely observation study with no intervention. Patients are exposed to septic shock and treatment according to standard departmental protocols at each centre.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.</intervention_name>
    <description>Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.</description>
    <arm_group_label>Adult patients with septic shock</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma isolated neutrophils bronchoalveolar lavage&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients admitted to participating ICUs with a presumptive diagnosis of&#xD;
        septic shock will be screened for eligibility. Patients fulfilling the Sepsis-III criteria&#xD;
        for septic shock will included. Study inclusion must occur within 12h of ICU admission.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients admitted to ICU and fulfilling the Sepsis-III criteria for septic shock&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Acute coronary syndromes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michelle Chew, MBBS, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Linkoeping University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle S Chew, MBBS, PHD</last_name>
    <phone>+46101030000</phone>
    <email>michelle.chew@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henrik Andersson, MSc, PhD</last_name>
    <phone>+46101030000</phone>
    <email>henrik.a.andersson@regionostergotland.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Anaesthesia and Intensive Care</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Andersson, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Helen Didriksson, RN</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Michelle Chew</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

